The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION JPMA Urges Takeda to Improve Promotion Regime over CASE-J
March 24, 2014
-
REGULATORY MHLW to Set Rules on OTC Switching of Diagnostics This Year
March 20, 2014
-
BUSINESS Eli Lilly Japan Sales Up 9% in 2013
March 19, 2014
-
ACADEMIA Trial Investigators Brush Aside Concerns over CASE-J in US Journal
March 18, 2014
-
ACADEMIA University of Tokyo Admits Patient Information on SIGN Trial Leaked to Novartis
March 17, 2014
-
REGULATORY Eligibility for Key Pricing Premium Up for Discussion: Govt
March 17, 2014
-
BUSINESS LEO Pharma to Carefully Ponder When to Begin Solo Marketing in Japan: Local Head
March 14, 2014
-
BUSINESS Otsuka to Disclose Patient-Level Clinical Trial Data
March 13, 2014
-
BUSINESS AstraZeneca, Osaka University Aim to Resurrect Ditched Drug Candidates
March 13, 2014
-
ORGANIZATION PhRMA “Disappointed” by Rule Changes for Foreign Price Adjustments: New Japan Committee Chair
March 12, 2014
-
REGULATORY Revisions of Prefectural Disaster Plans for Drug Distribution Almost Complete
March 11, 2014
-
BUSINESS Pfizer Japan Logs 1.2% Sales Increase in FY2013
March 10, 2014
-
BUSINESS Takeda Submits NDA for Once-Weekly DPP-4 Inhibitor Trelagliptin
March 10, 2014
-
ORGANIZATION FPMAJ Generic Guidelines Urge Makers to Create “Stable Supply” Officer Post
March 7, 2014
-
BUSINESS 28% of Mainstays to Face New Price Cuts for Long-Listed Drugs: Jiho Survey
March 7, 2014
-
BUSINESS New Price Cuts for Long-Listed Drugs to Pummel MTPC, Astellas: Jiho Tally
March 6, 2014
-
REGULATORY FY2014 NHI Revision Sees Price Cut of 5.64% without Tax Surcharges, 1,118 Long-Listed Products Subject to New Rule
March 5, 2014
-
BUSINESS Samsca Tops January “Mind Share” Ranking in HP Market
March 5, 2014
-
BUSINESS Takeda Apologizes for Violating Promotion Code, Inappropriate Expressions in Ads
March 4, 2014
-
BUSINESS Takeda’s Next Leader Weber to Take Up COO Role on April 1
March 3, 2014
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…